GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (LSE:IMM) » Definitions » YoY Rev. per Sh. Growth

ImmuPharma (LSE:IMM) YoY Rev. per Sh. Growth : 0.00% (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is ImmuPharma YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. ImmuPharma's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2023 was 0.00%.

ImmuPharma's Revenue per Share for the six months ended in Jun. 2023 was £0.00.

ImmuPharma YoY Rev. per Sh. Growth Historical Data

The historical data trend for ImmuPharma's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma YoY Rev. per Sh. Growth Chart

ImmuPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -100.00 -

ImmuPharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ImmuPharma YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

ImmuPharma's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2022 )
=(Revenue per Share (A: Dec. 2022 )-Revenue per Share (A: Dec. 2021 ))/ | Revenue per Share (A: Dec. 2021 ) |
=(0-0)/ | 0 |
=N/A %

ImmuPharma's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2023 )
=(Revenue per Share (Q: Jun. 2023 )-Revenue per Share (Q: Jun. 2022 )) / | Revenue per Share (Q: Jun. 2022 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuPharma YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of ImmuPharma's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuPharma (LSE:IMM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (LSE:IMM) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
LSE:ROQ AQSE:PBX LSE:BVX LSE:SAR LSE:SNG LSE:CIZ LSE:BSFA AQSE:INC LSE:VAL LSE:OCTP OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
IMM.GB:UK 25I:Germany
Address
One Bartholomew Close, London, GBR, EC1A 7BL
Website
https://www.immupharma.co.uk
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (LSE:IMM) Headlines

No Headlines